Pomerantz Law Firm Issues Warning on Class Action Lawsuit Against uniQure N.V. Due to Recent Stock Price Plunge

Investor Alert: Pomerantz Law Firm Responds to uniQure Stock Drop

In a recent announcement, Pomerantz LLP has alerted investors about a class action lawsuit filed against uniQure N.V., a prominent biotech firm listed on NASDAQ under the ticker QURE. This legal action comes in the wake of a significant downturn in uniQure's stock, which fell dramatically following critical feedback from the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy, AMT-130, intended for treating Huntington's disease.

On November 3, 2025, uniQure issued a press release detailing its conversation with the FDA during a pre-Biologics License Application (BLA) meeting. The company reported a concerning shift in the FDA's stance, indicating that the data from earlier Phase I/II studies may no longer be sufficient for BLA submission. The stock's reaction to this news was swift and severe, plunging by nearly 49.34% to close at $34.29 per share that day, marking a loss of $33.40 per share. This drastic decrease not only reflects investor unease but also highlights the potential ramifications of communications with regulatory agencies on biotech companies.

Pomerantz LLP is urging those who experienced financial losses due to their investment in uniQure to come forward. The firm is actively seeking individuals to join the class action lawsuit, especially those who bought shares during the class period. Interested parties must act before the deadline of April 13, 2026, to stand a chance of being appointed as Lead Plaintiff. Individuals looking for more information are encouraged to share their contact details with Pomerantz, which emphasizes its commitment to fighting for the rights of investors affected by corporate misconduct.

Founded by the influential Abraham L. Pomerantz, the firm holds a storied reputation in the realm of securities litigation and has a rich history of recovering substantial settlements for class members. With offices spanning major cities including New York, Chicago, and Los Angeles, Pomerantz LLP remains a leading force in legal advocacy for those wronged by securities fraud.

This class action centers around allegations that uniQure and its executives may have engaged in deceptive practices, leading to misleading information being disseminated to investors. As the lawsuit progresses, it will investigate the extent of the alleged securities fraud and its impact on investors. Pomerantz is poised to represent the class with diligence and an unwavering resolve to seek justice for its clients.

In light of this situation, potential investors and stakeholders in uniQure are advised to stay informed as developments unfold. The biotechnology sector often faces volatility due to regulatory updates and news from clinical trials, making it imperative for investors to remain vigilant and proactive in safeguarding their interests. The outcome of this case could have significant implications, not only for uniQure but also for investor confidence in the biotech industry as a whole.

For those interested in joining the class action or requiring further details, they can reach out to Danielle Peyton at Pomerantz LLP by e-mail or phone. Details are accessible on the firm's website, where legal documents and further information about the lawsuit can also be found.

As this story continues to develop, market watchers and potential class members will be keenly observing the next steps for uniQure and the unfolding of the legal proceedings initiated by Pomerantz LLP.